0N6A.F TME PHARM.CONF.IPO EO 1-
- Market cap
- EUR 9.98M
- P/E
- -
- P/B
- 5.94x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 0N6A.F undervalued?
Graham numberThe Graham number of TME PHARM.CONF.IPO EO 1- cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TME PHARM.CONF.IPO EO 1- fundamental analysis
No fundamental analysis for TME PHARM.CONF.IPO EO 1- yet.
TME PHARM.CONF.IPO EO 1- stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TME PHARM.CONF.IPO EO 1-
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It al…
Full company profileTME PHARM.CONF.IPO EO 1- financial statements
TME PHARM.CONF.IPO EO 1- annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -13.5M | -12.0M | -5.62M | -5.26M | -2.86M |
| EBITDA | - | -11.6M | -5.07M | -5.14M | -2.19M |
| Net Income | -14.5M | -15.1M | -6.74M | -5.72M | -3.29M |
| EPS | -13 | -5.93 | -0.29 | -0.06 | -0.03 |
| Balance Sheet | |||||
| Total Assets | 9.77M | 5.24M | 2.49M | 3.41M | 2.14M |
| Total Liabilities | 5.27M | 6.51M | 2.79M | 1.79M | 3.72M |
| Shareholders' Equity | 4.52M | -1.27M | -294K | 1.61M | -1.58M |
| Cash & Short-term Investments | 9.46M | 4.63M | 2.25M | 3.24M | 2.01M |
| Cash Flow | |||||
| Operating Cash Flow | -12.4M | -12.1M | -5.64M | -4.63M | -3.42M |
| Capital Expenditure | 14.0K | 21.0K | 19.0K | 16.0K | 0.00 |
| Free Cash Flow | -12.4M | -12.2M | -5.65M | -4.65M | -3.42M |
| Ratios | |||||
| ROE | -320.1% | - | - | -354.5% | - |
| ROA | -148.0% | -288.7% | -270.4% | -168.0% | -153.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
TME PHARM.CONF.IPO EO 1- dividends
TME PHARM.CONF.IPO EO 1- has not paid dividends in the last 5 fiscal years.
Last stock split: 1:100 on Jul 28, 2022.
Who owns TME PHARM.CONF.IPO EO 1-
- Insiders 0.00%
- Institutions 3.88%
- Public & others 96.12%
- Shares outstanding 96.7M
- Free float 91.5M
TME PHARM.CONF.IPO EO 1- company profile
- Company name
- TME PHARM.CONF.IPO EO 1-
- Ticker
- 0N6A.F
- ISIN
- NL0015000YE1
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- December
- Address
- Max-Dohrn-Strasse 8-10, Berlin, Germany, 10589
- Phone
- 49 30 16637082 0
- Website
- tmepharma.com
About TME PHARM.CONF.IPO EO 1-
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is headquartered in Berlin, Germany.
TME PHARM.CONF.IPO EO 1- management
3- Mr. Diede Mink van den OudenCEO & Member of Management Board · born 1981
- Dr. Aram Mangasarian M.B.A., Ph.D.Chief Scientific Officer & Member of Management Board · born 1970
- Dr. Jarl Ulf Jungnelius M.D., Ph.D.Chief Medical Officer & Member of Management Board · born 1951